JPRN-UMIN000018554招募中未知
Clinical Trial of Sofosbuvir/Ribavirin for HCV Genotype 2-infected Japanese Patients - Oral regimen for Genotype 2
Gunma University and affiliated hospitals0 个研究点目标入组 50 人开始时间: 2015年8月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who have allergy to sofosbuvir or ribavirin Patients with renal dysfunction Patients with less than 12 g/dl hemoglobin Patients expecting a child and have a possibility of pregnancy or who are breast-feeding Patients taking contraindicated drug Patients whom the doctor in attendance judged as inappropriate
研究者
相似试验
已完成
不适用
Prospective study of Sofosbuvir/Ribavirin for HCV genotype 2 infected Japanese patientsGenotype 2 infected chronic liver diseasesJPRN-UMIN000019399Osaka City University and affiliated hospitals250
已完成
3 期
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV InfectionHepatitis CNCT01896193Gilead Sciences127
已完成
2 期
Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian PatientsChronic Hepatitis C Virus InfectionNCT04385407Beni-Suef University203
已完成
2 期
Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV PatientsHepatitis CNCT01054729Gilead Sciences64
已完成
3 期
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)Chronic Hepatitis CNCT01604850Gilead Sciences202